MedPath

Stereotactic Radiosurgery in Treating Patients With Liver Metastases, Lung Metastases, or Other Advanced Solid Tumors

Phase 2
Completed
Conditions
Metastatic Cancer
Unspecified Adult Solid Tumor, Protocol Specific
Registration Number
NCT00006456
Lead Sponsor
Virginia Commonwealth University
Brief Summary

RATIONALE: Stereotactic radiosurgery delivers x-rays directly to the tumor and may cause less damage to normal tissue.

PURPOSE: Phase II trial to study the effectiveness of stereotactic radiosurgery in treating patients who have liver metastases, lung metastases, or other advanced solid tumors.

Detailed Description

OBJECTIVES:

* Determine the feasibility of fractionated stereotactic body radiosurgery in patients with advanced extracranial tumors.

* Assess the toxicities of this treatment regimen in these patients.

* Determine tumor response and cause of death in these patients treated with this regimen.

OUTLINE: Patients receive fractionated stereotactic body radiosurgery over 30 minutes for 5-10 days for a total of 3 treatments.

Patients are followed every 3 months.

PROJECTED ACCRUAL: A total of 10-25 patients will be accrued within 2-3 years.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
26
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Massey Cancer Center

🇺🇸

Richmond, Virginia, United States

© Copyright 2025. All Rights Reserved by MedPath